ASX:CSLBiotechs
Assessing CSL (ASX:CSL) Valuation After Expanded Buy Back And New Canadian Vaccine Contract
CSL (ASX:CSL) is back in focus after two fresh developments: a larger on market share buy back now covering nearly four million shares, and a new Canadian pandemic influenza vaccine contract for CSL Seqirus.
See our latest analysis for CSL.
Despite the fresh buy back and the Canadian vaccine contract, CSL's share price has had a weak patch, with a 30 day share price return of 19.5% and a 1 year total shareholder return decline of 42.6%, pointing to fading momentum after several tougher...